BIOLOGICAL · Unmapped registry intervention
HER-2 pulsed DC1
Find medicine records ·
Find other trials using this name
Clinical trial
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
NCT05325632
Drugs and interventions used in this trial
5 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Trastuzumab
Normalized identity: trastuzumabView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Pertuzumab
Normalized identity: pertuzumabView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Paclitaxel
Normalized identity: paclitaxelView linked drug · Find medicine records ·
Find other trials using this name
PROCEDURE · Unmapped registry intervention
Resection surgery
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedStudy of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
HER2-positive Breast Cancerunresolved
Interventions
HER-2 pulsed DC1BIOLOGICAL
TrastuzumabDRUG · verified · RxNorm: trastuzumab
PertuzumabDRUG · verified · RxNorm: pertuzumab
PaclitaxelDRUG · verified · RxNorm: paclitaxel
Resection surgeryPROCEDURE
Sponsors & collaborators
ImmunoRestorationcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05325632 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.